Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
FRA:1M7's 9-Day RSI is ranked better than 80.54% of 699
companies
in the Healthcare Providers & Services industry
Industry Median: 48.59
vs FRA:1M7: 41.85
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Cambridge Cognition Holdings 9-Day RSI Related Terms
FRA:1M7 vs VEEV, BTSG, TEM: 9-Day RSI Comparison
For the Health Information Services subindustry, Cambridge Cognition Holdings's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Cognition Holdings 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cambridge Cognition Holdings's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Cambridge Cognition Holdings's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Cognition Holdings (FRA:1M7) has a 9-Day RSI of 41.85 as of Jul. 21, 2026. According to the industry distribution chart, Cambridge Cognition Holdings ranks #136 out of 699 companies in the Healthcare Providers & Services industry, placing it in the top 19.5%.
Is Cambridge Cognition Holdings' 9-Day RSI too high?
Cambridge Cognition Holdings' current 9-Day RSI is 41.85. The Healthcare Providers & Services industry median 9-Day RSI is 48.59. Cambridge Cognition Holdings' value of 41.85 is 13.9% below this industry median. Based on the distribution chart, Cambridge Cognition Holdings ranks #136 out of 699 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Cambridge Cognition Holdings has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cambridge Cognition Holdings' 9-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cambridge Cognition Holdings ranks #136 out of 699 companies for 9-Day RSI. This places Cambridge Cognition Holdings in the top 20% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 48.59. Cambridge Cognition Holdings' value of 41.85 is 13.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 48.59, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambridge Cognition Holdings's current 9-Day RSI of 41.85 is 13.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 48.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Cognition Holdings's current 9-Day RSI is 41.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Cognition Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Cognition Holdings (FRA:1M7) is currently considered Fairly Valued. The stock's GF Value™ is €0.35, compared to a current price of €0.35 — trading 1.1% below its estimated fair value. The current 9-Day RSI is 41.85 and 13.9% below the Healthcare Providers & Services industry median of 48.59. Cambridge Cognition Holdings' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Cambridge Cognition Holdings (FRA:1M7), the current 9-Day RSI is 41.85 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cambridge Cognition Holdings (FRA:1M7) Overvalued in 2026?
Based on GuruFocus' analysis, Cambridge Cognition Holdings stock appears to be undervalued.
The current stock price of €0.35 is trading 1.1% below its estimated GF Value™ of €0.35.
GuruFocus considers Cambridge Cognition Holdings to be Fairly Valued.
Key valuation signals for FRA:1M7:
9-Day RSI: 41.85
GF Value™: €0.35 vs. price of €0.35 (1.1% below fair value)
Industry Position: 13.9% below the Healthcare Providers & Services median (#136 of 699)
No single metric tells the full story. See the FRA:1M7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
52GF Score
Get the complete analysis for FRA:1M7
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1M7 has been successfully added to your 
